Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Dec;74(6):2136–2143. doi: 10.1172/JCI111639

Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

E Slatopolsky, C Weerts, J Thielan, R Horst, H Harter, K J Martin
PMCID: PMC425405  PMID: 6549016

Abstract

Current evidence suggests that administration of 1,25(OH)2D3 to patients with chronic renal insufficiency results in suppression of secondary hyperparathyroidism only if hypercalcemia occurs. However, since the parathyroid glands possess specific receptors for 1,25(OH)2D3 and a calcium binding protein, there is considerable interest in a possible direct effect of 1,25(OH)2D3 on parathyroid hormone (PTH) secretion independent of changes in serum calcium. Recent findings indicate substantial degradation of 1,25(OH)2D3 in the intestine, therefore, it is possible that while oral administration of the vitamin D metabolite increases intestinal calcium absorption, the delivery of 1,25(OH)2D3 to peripheral target organs may be limited. We therefore compared the effects of orally or intravenously administered 1,25(OH)2D3 on the plasma levels of 1,25(OH)2D3 and the effects of these two modes of treatment on PTH secretion. Whereas oral administration of 1,25(OH)2D3 in doses adequate to maintain serum calcium at the upper limits of normal did not alter PTH levels, a marked suppression (70.1 +/- 3.2%) of PTH levels was seen in all 20 patients given intravenous 1,25(OH)2D3. Temporal studies suggested a 20.1 +/- 5.2% decrease in PTH without a significant change in serum calcium with intravenous 1,25(OH)2D3. In five patients the serum calcium was increased by the oral administration of calcium carbonate, the decrement in serum i-PTH was only 25 +/- 6.65% when compared with 73.5 +/- 5.08% (P less than 0.001) obtained by the administration of intravenous 1,25(OH)2D3. Thus, a similar serum calcium achieved by intravenous 1,25(OH)2D3 rather than calcium carbonate has a greater suppressive effect in the release of PTH. These studies indicate that 1,25(OH)2D3 administered intravenously rather than orally may result in a greater delivery of the vitamin D metabolite to peripheral target tissues other than the intestine and allow a greater expression of biological effects of 1,25(OH)2D3 in peripheral tissues. The use of intravenous 1,25(OH)2D3 thus provides a simple and extremely effective way to suppress secondary hyperparathyroidism in dialysis patients.

Full text

PDF
2136

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnaud C. D. Hyperparathyroidism and renal failure. Kidney Int. 1973 Aug;4(2):89–95. doi: 10.1038/ki.1973.87. [DOI] [PubMed] [Google Scholar]
  2. Bellorin-Font E., Martin K. J., Freitag J. J., Anderson C., Sicard G., Slatopolsky E., Klahr S. Altered adenylate cyclase kinetics in hyperfunctioning human parathyroid glands. J Clin Endocrinol Metab. 1981 Mar;52(3):499–507. doi: 10.1210/jcem-52-3-499. [DOI] [PubMed] [Google Scholar]
  3. Berl T., Berns A. S., Hufer W. E., Hammill K., Alfrey A. C., Arnaud C. D., Schrier R. W. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med. 1978 Jun;88(6):774–780. doi: 10.7326/0003-4819-88-6-774. [DOI] [PubMed] [Google Scholar]
  4. Brown E. M. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab. 1983 Mar;56(3):572–581. doi: 10.1210/jcem-56-3-572. [DOI] [PubMed] [Google Scholar]
  5. Brown E. M., Wilson R. E., Eastman R. C., Pallotta J., Marynick S. P. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982 Jan;54(1):172–179. doi: 10.1210/jcem-54-1-172. [DOI] [PubMed] [Google Scholar]
  6. Brumbaugh P. F., Haussler D. H., Bressler R., Haussler M. R. Radioreceptor assay for 1 alpha,25-dihydroxyvitamin D3. Science. 1974 Mar 15;183(4129):1089–1091. doi: 10.1126/science.183.4129.1089. [DOI] [PubMed] [Google Scholar]
  7. Brumbaugh P. F., Hughes M. R., Haussler M. R. Cytoplasmic and nuclear binding components for 1alpha25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci U S A. 1975 Dec;72(12):4871–4875. doi: 10.1073/pnas.72.12.4871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Canterbury J. M., Lerman S., Claflin A. J., Henry H., Norman A., Reiss E. Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest. 1978 May;61(5):1375–1383. doi: 10.1172/JCI109055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chertow B. S., Baylink D. J., Wergedal J. E., Su M. H., Norman A. W. Decrease in serum immunoreactive parathyroid hormone in rats and in parathyroid hormone secretion in vitro by 1,25-dihydroxycholecalciferol. J Clin Invest. 1975 Sep;56(3):668–678. doi: 10.1172/JCI108137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cheung A. K., Manolagas S. C., Catherwood B. D., Mosely C. A., Jr, Mitas J. A., 2nd, Blantz R. C., Deftos L. J. Determinants of serum 1,25(OH)2D levels in renal disease. Kidney Int. 1983 Jul;24(1):104–109. doi: 10.1038/ki.1983.131. [DOI] [PubMed] [Google Scholar]
  11. Christiansen C., Christensen M. S., Melsen F., Rødbro P., DeLuca H. F. Mineral metabolism in chronic renal failure with special reference to serum concentrations of 1.25(OH)2D and 24.25(OH)2D. Clin Nephrol. 1981 Jan;15(1):18–22. [PubMed] [Google Scholar]
  12. Dietel M., Dorn G., Montz R., Altenähr E. Influence of vitamin D3, 1,25-dihydroxyvitamin D3, and 24,25-dihydroxyvitamin D3 on parathyroid hormone secretion, adenosine 3',5'-monophosphate release, and ultrastructure of parathyroid glands in organ culture. Endocrinology. 1979 Jul;105(1):237–245. doi: 10.1210/endo-105-1-237. [DOI] [PubMed] [Google Scholar]
  13. Fraser D. R., Kodicek E. Regulation of 25-hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nat New Biol. 1973 Feb 7;241(110):163–166. doi: 10.1038/newbio241163a0. [DOI] [PubMed] [Google Scholar]
  14. Garabedian M., Holick M. F., Deluca H. F., Boyle I. T. Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci U S A. 1972 Jul;69(7):1673–1676. doi: 10.1073/pnas.69.7.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Golden P., Greenwalt A., Martin K., Bellorin-Font E., Mazey R., Klahr S., Slatopolsky E. Lack of a direct effect of 1,25-dihydroxycholecalciferol on parathyroid hormone secretion by normal bovine parathyroid glands. Endocrinology. 1980 Aug;107(2):602–607. doi: 10.1210/endo-107-2-602. [DOI] [PubMed] [Google Scholar]
  16. Henry H. L., Norman A. W. Studies on the mechanism of action of calciferol VII. Localization of 1,25-dihydroxy-vitamin D3 in chick parathyroid glands. Biochem Biophys Res Commun. 1975 Feb 17;62(4):781–788. doi: 10.1016/0006-291x(75)90391-5. [DOI] [PubMed] [Google Scholar]
  17. Horst R. L., Littledike E. T., Riley J. L., Napoli J. L. Quantitation of vitamin D and its metabolites and their plasma concentrations in five species of animals. Anal Biochem. 1981 Sep 1;116(1):189–203. doi: 10.1016/0003-2697(81)90344-4. [DOI] [PubMed] [Google Scholar]
  18. Hruska K. A., Kopelman R., Rutherford W. E., Klahr S., Slatopolsky E., Greenwalt A., Bascom T., Markham J. Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest. 1975 Jul;56(1):39–48. doi: 10.1172/JCI108077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hughes M. R., Brumbaugh P. F., Hussler M. R., Wergedal J. E., Baylink D. J. Regulation of serum 1alpha,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975 Nov 7;190(4214):578–580. doi: 10.1126/science.1188357. [DOI] [PubMed] [Google Scholar]
  20. Llach F., Coburn J. W., Brickman A. S., Kurokawa K., Norman A. W., Canterbury J. M., Reiss E. Acute actions of 1,25-dihydroxy-vitamin D3 in normal man: effect on calcium and parathyroid status. J Clin Endocrinol Metab. 1977 Jun;44(6):1054–1060. doi: 10.1210/jcem-44-6-1054. [DOI] [PubMed] [Google Scholar]
  21. Madsen S., Olgaard K., Ladefoged J. Suppressive effect of 1,25-dihydroxyvitamin D3 on circulating parathyroid hormone in acute renal failure. J Clin Endocrinol Metab. 1981 Oct;53(4):823–827. doi: 10.1210/jcem-53-4-823. [DOI] [PubMed] [Google Scholar]
  22. Oldham S. B., Fischer J. A., Shen L. H., Arnaud C. D. Isolation and properties of a calcium-binding protein from porcine parathyroid glands. Biochemistry. 1974 Nov 5;13(23):4790–4796. doi: 10.1021/bi00720a017. [DOI] [PubMed] [Google Scholar]
  23. Oldham S. B., Smith R., Hartenbower D. L., Henry H. L., Norman A. W., Coburn J. W. The acute effects of 1,25-dihydroxycholecalciferol on serum immunoreactive parathyroid hormone in the dog. Endocrinology. 1979 Jan;104(1):248–254. doi: 10.1210/endo-104-1-248. [DOI] [PubMed] [Google Scholar]
  24. Rasmussen H., Matsumoto T., Fontaine O., Goodman D. B. Role of changes in membrane lipid structure in the action of 1,25-dihydroxyvitamin D3. Fed Proc. 1982 Jan;41(1):72–77. [PubMed] [Google Scholar]
  25. Reiss E., Canterbury J. M., Egdahl R. H. Experience with a radioimmunoassay of parathyroid hormone in human sera. Trans Assoc Am Physicians. 1968;81:104–115. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES